$PLSE
Pulse Biosciences Inc Stock $plse

$plse Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923013952 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$444.0K
YoY Change	-100.0%	-100.0%
Cost Of Revenue	$0.00	$0.00	$909.0K
YoY Change	-100.0%	-100.0%
Gross Profit	$0.00	$0.00	-$465.0K
YoY Change	-100.0%	-100.0%
Gross Profit Margin			-104.73%
Selling, General & Admin	$3.530M	$3.733M	$10.04M
YoY Change	-52.79%	-62.82%	12.04%
% of Gross Profit
Research & Development	$6.697M	$5.829M	$6.769M
YoY Change	22.7%	-13.89%	-25.31%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K	$200.0K
YoY Change	-50.0%	-50.0%	100.0%
% of Gross Profit
Operating Expenses	$6.697M	$5.829M	$6.769M
YoY Change	22.7%	-13.89%	-63.46%
Operating Profit	-$10.23M	-$9.562M	-$17.27M
YoY Change	-27.02%	-44.64%	-6.76%
Interest Expense	$317.0K	-$239.0K	$0.00
YoY Change	1661.11%		-100.0%
% of Operating Profit
Other Income/Expense, Net	$317.0K	-$239.0K	$0.00
YoY Change	1661.11%		-100.0%
Pretax Income	-$9.910M	-$9.801M	-$17.27M
YoY Change	-29.19%	-43.26%	-7.33%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.910M	-$9.801M	-$17.30M
YoY Change	-29.19%	-43.35%	-7.18%
Net Earnings / Revenue			-3896.4%
Basic Earnings Per Share	-$0.22	-$0.26	-$0.58
Diluted Earnings Per Share	-$0.22	-$0.26	-$580.7K
COMMON SHARES
Basic Shares Outstanding	37.64M	37.59M	29.80M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.75M	$54.10M	$12.68M
YoY Change	296.99%	326.78%	-78.83%
Cash & Equivalents	$58.75M	$54.10M	$12.68M
Short-Term Investments
Other Short-Term Assets	$1.211M	$849.0K	$1.979M
YoY Change	14.03%	-57.1%	106.15%
Inventory			$7.487M
Prepaid Expenses
Receivables			$21.00K
Other Receivables			$0.00
Total Short-Term Assets	$59.96M	$54.95M	$22.16M
YoY Change	152.57%	147.92%	-64.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.755M	$1.865M	$2.554M
YoY Change	-26.45%	-26.98%	5.1%
Goodwill	$2.791M	$2.791M	$2.791M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$365.0K	$365.0K	$365.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$14.80M	$15.27M	$17.37M
YoY Change	-12.21%	-12.07%	-6.51%
TOTAL ASSETS
Total Short-Term Assets	$59.96M	$54.95M	$22.16M
Total Long-Term Assets	$14.80M	$15.27M	$17.37M
Total Assets	$74.76M	$70.22M	$39.53M
YoY Change	84.14%	77.62%	-50.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.794M	$2.160M	$3.486M
YoY Change	-7.91%	-38.04%	61.09%
Accrued Expenses	$2.844M	$3.091M	$4.604M
YoY Change	-40.21%	-32.86%	-18.03%
Deferred Revenue		$4.000K	$16.00K
YoY Change		-75.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$801.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$5.613M	$6.991M	$8.905M
YoY Change	-25.79%	-21.49%	4.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$65.00M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$8.644M	$8.898M	$9.833M
YoY Change	-10.13%	-9.51%	-7.5%
Total Long-Term Liabilities	$8.644M	$73.90M	$9.833M
YoY Change	-10.13%	651.53%	-80.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.613M	$6.991M	$8.905M
Total Long-Term Liabilities	$8.644M	$73.90M	$9.833M
Total Liabilities	$14.26M	$80.89M	$18.74M
YoY Change	-17.02%	331.68%	-68.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$314.4M	-$304.5M	-$253.5M
YoY Change	17.54%	20.12%	32.6%
Common Stock	$374.9M	$293.8M	$274.3M
YoY Change	28.89%	7.13%	29.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.50M	-$10.67M	$20.80M
YoY Change
Total Liabilities & Shareholders Equity	$74.76M	$70.22M	$39.53M
YoY Change	84.14%	77.62%	-50.92%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$9.910M	-$9.801M	-$17.30M
YoY Change	-29.19%	-43.35%	-7.18%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$200.0K
YoY Change	-50.0%	-50.0%	100.0%
Cash From Operating Activities	-$9.202M	-$6.570M	-$15.60M
YoY Change	-28.23%	-57.88%	33.48%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	$39.00K	$279.0K
YoY Change	-184.21%	-86.02%	447.06%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$16.00K	-$39.00K	-$279.0K
YoY Change	-15.79%	-86.02%	-103.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.87M	-$432.0K	-65.00K
YoY Change	-7.32%	564.62%	-100.13%
NET CHANGE
Cash From Operating Activities	-9.202M	-$6.570M	-15.60M
Cash From Investing Activities	-16.00K	-$39.00K	-279.0K
Cash From Financing Activities	13.87M	-$432.0K	-65.00K
Net Change In Cash	4.649M	-$7.041M	-15.94M
YoY Change	119.09%	-55.84%	-133.62%
FREE CASH FLOW
Cash From Operating Activities	-$9.202M	-$6.570M	-$15.60M
Capital Expenditures	$16.00K	$39.00K	$279.0K
Free Cash Flow	-$9.218M	-$6.609M	-$15.88M
YoY Change	-28.0%	-58.38%	35.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37593000
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37593000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37235000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37235000
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	usd
CY2023Q1	plse	Controlled Launch Program Expenses ControlledLaunchProgramExpenses	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-34899
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5696597
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3957 Point Eden Way
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Hayward
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94545
CY2023Q1	dei	City Area Code CityAreaCode	510
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	906-4600
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	PLSE
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37641892
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54098000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61139000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	849000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1008000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	54947000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	62147000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1865000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1961000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2384000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2551000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2791000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2791000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7869000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8062000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	365000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	365000	usd
CY2023Q1	us-gaap	Assets Assets	70221000	usd
CY2022Q4	us-gaap	Assets Assets	77877000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2160000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1573000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3091000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2595000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	935000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	896000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	801000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	917000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6991000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5981000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8898000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9144000	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	65000000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	65000000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	80889000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	80125000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	37000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	293801000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	292420000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-304506000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294705000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-10668000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2248000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70221000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77877000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	444000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	909000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5829000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6769000	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0	usd
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	5541000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3733000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4498000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	9562000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	17717000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9562000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17273000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-239000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-239000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9801000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17273000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9801000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17273000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9801000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17273000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37390000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29745000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9801000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17273000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	135000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	160000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	166000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	896000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2007000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-40000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1663000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-160000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-191000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	39000	usd
CY2023Q1	plse	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-193000	usd
CY2022Q1	plse	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-174000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	587000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	609000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	496000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	215000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-207000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-182000	usd
CY2023Q1	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	801000	usd
CY2022Q1	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6570000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15594000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	279000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-279000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	291000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	372000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	194000	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	437000	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	917000	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-432000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-65000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7041000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15938000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	61139000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28614000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54098000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12676000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	-0	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	27000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2248000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	291000	usd
CY2023Q1	plse	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	194000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	896000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9801000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-10668000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35690000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	372000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2007000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17273000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	20796000	usd
CY2022Q4	plse	Accrued Clinical Trial Fees And Costs AccruedClinicalTrialFeesAndCosts	64000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	351000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	318000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	50000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the condensed consolidated financial statements. Estimates include, but are <em style="font: inherit;">not</em> limited to, the valuation of cash equivalents, the valuation and recognition of share-based compensation, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1615000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1377000	usd
CY2023Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	815000	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	50000	usd
CY2021Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	80000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	0	usd
CY2022Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	17000	usd
CY2023Q1	plse	Adjustment For Inventory At Cost AdjustmentForInventoryAtCost	0	usd
CY2022Q1	plse	Adjustment For Inventory At Cost AdjustmentForInventoryAtCost	0	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	50000	usd
CY2022Q1	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	97000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12816403
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5558884
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	571000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	50700000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	57973000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4953000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4914000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3088000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2953000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1865000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1961000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5601000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5434000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2384000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2551000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	498000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	665000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	665000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	556000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2384000	usd
CY2023Q1	plse	Accrued Clinical Trial Fees And Costs AccruedClinicalTrialFeesAndCosts	49000	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual Current StandardProductWarrantyAccrualCurrent	50000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	211000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	215000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3091000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2595000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2007000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2007000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7869000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8062000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	935000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	896000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8898000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9144000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9833000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10040000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	453000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	447000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1392000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1910000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1977000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2046000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2117000	usd
CY2023Q1	plse	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	4075000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13517000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3684000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9833000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M2D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	usd
CY2021Q1	plse	Number Of Ko Ls NumberOfKOLs	70	pure
CY2022Q1	plse	Controlled Launch Program Expenses ControlledLaunchProgramExpenses	300000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	400000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	444000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	444000	usd

Files In Submission

Name	View Source	Status
plse-20230331_lab.xml	Edgar Link	unprocessable
plse-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001437749-23-013952-index-headers.html	Edgar Link	pending
0001437749-23-013952-index.html	Edgar Link	pending
0001437749-23-013952.txt	Edgar Link	pending
0001437749-23-013952-xbrl.zip	Edgar Link	pending
ex_504219.htm	Edgar Link	pending
ex_504221.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plse-20230331.xsd	Edgar Link	pending
plse20230331_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
plse-20230331_def.xml	Edgar Link	unprocessable
plse-20230331_pre.xml	Edgar Link	unprocessable
plse20230331_10q_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLSE
Pulse Biosciences Inc Stock $plse

2023 Q2 Form 10-Q Financial Statement

#000143774923013952 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSE Pulse Biosciences Inc Stock $plse

2023 Q2 Form 10-Q Financial Statement

#000143774923013952 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSE
Pulse Biosciences Inc Stock $plse